RESOURCES

Browse our content

Articles

How standardized viral vector platforms can drive better service from CDMOs

July 12, 2022

Webinars

Joint webinar with Pall Corporations – Pall’s Accelerator℠ Integrated Solutions: Supporting Exothera to meet the high demand for viral vector GMP manufacturing.

June 21, 2022

Podcasts

Using End-to-End Integrated Solutions to meet the High Demand for Viral Vector GMP Manufacturing

June 14, 2022

Webinars

Joint webinar with POLYPLUS – Taking a right first-time approach to optimize end-to-end viral vector manufacturing

June 9, 2022

Reports

Biopharma CDMO Benchmark Report – What customers want from their CDMO

April 15, 2022

Articles

Serum-based media concerns in viral vector manufacturing

March 15, 2022

Articles

Are modern scalable bioreactors the right cell culture strategy for gene and cell therapy success?

January 31, 2022

Articles

Gene and cell therapy manufacturing: how to design your stable cell line strategy?

January 5, 2022

Posters

Adaptation of suspension-based Adenovirus production process to scale-X™ technology

December 21, 2021

White Papers

The landscape for viral vector upstream processes – PROS and CONS

December 11, 2021

Brochures

Exothera Capabilities

October 19, 2021

Infographics

Timeline of viral vector-based Cell & Gene therapy approvals

May 6, 2021

Infographics

Worldwide approved gene therapies based on viral vectors

February 21, 2021

Infographics

Plasmid manufacturing capacity around the world

November 30, 2020